Regeneron Pharmaceuticals (NASDAQ:REGN) Rating Increased to Buy at Wall Street Zen

Regeneron Pharmaceuticals (NASDAQ:REGN) was upgraded by investment analysts at Wall Street Zen from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Saturday.

A number of other equities research analysts have also recently issued reports on the company. Evercore boosted their price objective on Regeneron Pharmaceuticals from $750.00 to $875.00 and gave the stock an “outperform” rating in a report on Thursday, January 22nd. HSBC began coverage on Regeneron Pharmaceuticals in a report on Monday, November 24th. They set a “buy” rating and a $255.00 price target for the company. Morgan Stanley upped their price objective on Regeneron Pharmaceuticals from $768.00 to $769.00 and gave the company an “equal weight” rating in a report on Monday, February 2nd. Scotiabank lifted their target price on Regeneron Pharmaceuticals from $650.00 to $770.00 and gave the stock a “sector perform” rating in a report on Monday, November 24th. Finally, JPMorgan Chase & Co. boosted their target price on shares of Regeneron Pharmaceuticals from $850.00 to $950.00 and gave the company an “overweight” rating in a research report on Monday, February 2nd. Two analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and nine have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $793.81.

Regeneron Pharmaceuticals Price Performance

NASDAQ:REGN opened at $781.67 on Friday. The company has a market cap of $82.64 billion, a P/E ratio of 18.81, a P/E/G ratio of 2.07 and a beta of 0.40. The firm’s fifty day moving average price is $771.59 and its two-hundred day moving average price is $680.78. Regeneron Pharmaceuticals has a one year low of $476.49 and a one year high of $821.11. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.13 and a quick ratio of 3.39.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its earnings results on Friday, January 30th. The biopharmaceutical company reported $11.44 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $10.74 by $0.70. Regeneron Pharmaceuticals had a net margin of 31.41% and a return on equity of 13.04%. The company had revenue of $3.88 billion during the quarter, compared to analysts’ expectations of $3.76 billion. During the same quarter last year, the company posted $12.07 EPS. Regeneron Pharmaceuticals’s quarterly revenue was up 2.5% compared to the same quarter last year. Equities analysts expect that Regeneron Pharmaceuticals will post 35.92 earnings per share for the current year.

Insider Buying and Selling

In other news, Director Arthur F. Ryan sold 100 shares of the business’s stock in a transaction that occurred on Monday, February 9th. The shares were sold at an average price of $778.53, for a total value of $77,853.00. Following the completion of the transaction, the director directly owned 17,803 shares in the company, valued at approximately $13,860,169.59. The trade was a 0.56% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Bonnie L. Bassler sold 1,500 shares of the stock in a transaction that occurred on Wednesday, January 7th. The stock was sold at an average price of $800.00, for a total transaction of $1,200,000.00. Following the sale, the director owned 1,703 shares in the company, valued at $1,362,400. This represents a 46.83% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 5,274 shares of company stock worth $4,142,738 in the last ninety days. 7.02% of the stock is owned by company insiders.

Institutional Investors Weigh In On Regeneron Pharmaceuticals

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Insigneo Advisory Services LLC increased its stake in shares of Regeneron Pharmaceuticals by 3.0% in the fourth quarter. Insigneo Advisory Services LLC now owns 445 shares of the biopharmaceutical company’s stock valued at $343,000 after buying an additional 13 shares during the period. Guardian Wealth Advisors LLC NC grew its holdings in Regeneron Pharmaceuticals by 3.3% during the 4th quarter. Guardian Wealth Advisors LLC NC now owns 443 shares of the biopharmaceutical company’s stock worth $342,000 after acquiring an additional 14 shares during the last quarter. TD Private Client Wealth LLC increased its position in Regeneron Pharmaceuticals by 9.7% in the 4th quarter. TD Private Client Wealth LLC now owns 169 shares of the biopharmaceutical company’s stock valued at $130,000 after acquiring an additional 15 shares during the period. MCF Advisors LLC increased its position in Regeneron Pharmaceuticals by 50.0% in the 4th quarter. MCF Advisors LLC now owns 45 shares of the biopharmaceutical company’s stock valued at $35,000 after acquiring an additional 15 shares during the period. Finally, Rexford Capital Inc. raised its stake in shares of Regeneron Pharmaceuticals by 5.5% during the fourth quarter. Rexford Capital Inc. now owns 288 shares of the biopharmaceutical company’s stock valued at $222,000 after acquiring an additional 15 shares during the last quarter. 83.31% of the stock is currently owned by institutional investors.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.